Partnering News

2008-09-30
Bayer starts new research cooperation in Asia
Research collaboration with National University of Singapore signed
Overall investment volume of 10 million Euro

Bayer Schering Pharma and the National University of Singapore (NUS) have agreed to cooperate in the field of pre-clinical cancer research. The initial collaboration with the NUS will focus on three joint projects in the field of oncology. more

2008-09-16
Bayer HealthCare acquires German DIREVO Biotech AG
Strengthening Bayer HealthCare’s commitment to develop innovative biologicals

Bayer HealthCare AG acquires the German biotech company DIREVO Biotech AG, Cologne. With the acquisition of the biotech company specialized in protein engineering, Bayer strengthens the research competence in biologicals of its pharmaceutical division Bayer Schering Pharma more

2008-09-10
Bayer Intensifies Research in Early Diagnosis of Alzheimer’s Disease
Licensing agreement with Nagasaki University signed

Bayer Schering Pharma and the University of Nagasaki (Japan) have signed a licensing agreement on the use of novel substances for molecular imaging. Being used as tracers in Positron Emission Tomography (PET), these compounds could make it possible to allow an early diagnosis of Alzheimer’s disease. more

2008-08-08
Bayer Acquires Preclinical Anti-cancer Program from Nycomed
Bayer Schering Pharma AG, Germany, is expanding its oncology pipeline with the acquisition of a preclinical oncology program from Nycomed, a pharmaceutical company headquartered in Switzerland. The agreement comprises two potential drug candidates and an extensive set of back-up compounds targeting a kinase critical for growth and survival of cancer cells. more

2008-07-02
Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen
Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen’s hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in the third quarter of 2008. The total transaction is valued at US-Dollar 90 million upfront with a final, potential milestone payment of US-Dollar 30 million. This agreement includes a license to use Maxygen’s MolecularBreeding™ technology, a novel research platform, for exploiting gene targets. more